EVP & Chief Financial Officer Bezerra Eduardo Guarita was granted 26,738 units of Ordinary Shares, covered exercise/tax liability with 7,782 units of Ordinary Shares and exercised 4,870 units of Ordinary Shares at a strike of $28.68, increasing direct ownership by 154% to 39,285 units (SEC Form 4)

$PRGO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PRGO alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bezerra Eduardo Guarita

(Last) (First) (Middle)
C/O PERRIGO COMPANY PLC
515 EASTERN AVENUE

(Street)
ALLEGAN MI 49010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PERRIGO Co plc [ PRGO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 03/07/2025 A(1) 26,738 A $27.76 42,197 D
Ordinary Shares 03/07/2025 F 6,511 D $27.76 35,686 D
Ordinary Shares 03/06/2025 M 4,870 A $28.68 40,556 D
Ordinary Shares 03/06/2025 F 1,271 D $28.68 39,285 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 03/06/2025 A 9,960 (3) (3) Ordinary Shares 9,960 (2) 9,960 D
Restricted Stock Units (4) 03/06/2025 M 4,870 (5) (5) Ordinary Shares 4,870 (4) 4,870 D
Explanation of Responses:
1. Vesting of performance-based restricted stock units granted on June 7, 2022.
2. Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.
3. Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 2 equal annual installments beginning 6 March 2026.
4. Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.
5. Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 6 March 2024.
Remarks:
/s/ Victor Torres, attorney-in-fact for Mr. Eduardo Bezerra 03/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $PRGO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRGO

DatePrice TargetRatingAnalyst
1/14/2025Buy → Hold
Argus
1/6/2025$34.00 → $27.00Overweight → Neutral
Piper Sandler
9/24/2024$50.00 → $30.00Hold
Jefferies
11/17/2023$37.00Overweight
Piper Sandler
3/7/2023$49.00Buy
Canaccord Genuity
9/14/2022$46.00Hold → Buy
Argus
9/6/2022$48.00 → $54.00Equal Weight → Overweight
Wells Fargo
11/11/2021$59.00 → $55.00Outperform
Raymond James
More analyst ratings

$PRGO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day

    DUBLIN, Feb. 28, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that at its Virtual Investor Day, scheduled to begin today at 8:00 AM EST, the management team will lay out its plan to consumerize, simplify and scale its global self-care platform, with a clear path to return to stable and reliable performance. Perrigo's unique complementary businesses enables each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company's key

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations

    Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value Accretive Growth Delivered Fiscal Year 2024 Adjusted EPS of $2.57 the Mid-Point of the Company's Communicated Guidance Range, on Reported Loss of $(1.17) Per Share Fourth Quarter 2024 Infant formula Net Sales Grew 17% Compared to the Prior Year Quarter, Due Primarily to Market Share Gains1 and Recovering Customer Inventory Levels DUBLIN, Feb. 27, 2025 /PRNewswire/ -- Fourth Quarter 2024 Highlights: Net sales of $1.14 billion declined 1.6%, as organic gr

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Perrigo to Attend the UBS 2025 Global Consumer and Retail Conference

    DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS 2025 Global Consumer and Retail Conference, on Wednesday, March 12 at 10 AM ET in New York City.  Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. About Perrigo  Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (O

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRGO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PRGO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PRGO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PRGO
SEC Filings

See more

$PRGO
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

    For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRGO
Leadership Updates

Live Leadership Updates

See more
  • Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

    Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary

    Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. President and CEO Patrick Lockwood-Taylor commented, "I am very excited to welcome Charles to the Perrigo leadership team. His strat

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer

    DUBLIN, Aug. 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. He will also evaluate untapped market opportunities and develop strategies to scale the Company's brand-building efforts.

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRGO
Financials

Live finance-specific insights

See more
  • Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day

    DUBLIN, Feb. 28, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that at its Virtual Investor Day, scheduled to begin today at 8:00 AM EST, the management team will lay out its plan to consumerize, simplify and scale its global self-care platform, with a clear path to return to stable and reliable performance. Perrigo's unique complementary businesses enables each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company's key

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations

    Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value Accretive Growth Delivered Fiscal Year 2024 Adjusted EPS of $2.57 the Mid-Point of the Company's Communicated Guidance Range, on Reported Loss of $(1.17) Per Share Fourth Quarter 2024 Infant formula Net Sales Grew 17% Compared to the Prior Year Quarter, Due Primarily to Market Share Gains1 and Recovering Customer Inventory Levels DUBLIN, Feb. 27, 2025 /PRNewswire/ -- Fourth Quarter 2024 Highlights: Net sales of $1.14 billion declined 1.6%, as organic gr

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Perrigo Increases Quarterly Dividend by 5%

    DUBLIN, Feb. 19, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors has approved a 5% increase in the Company's quarterly dividend to $0.290 per share, or $1.16 per share on an annual basis, up from $0.276 per share. This marks the 22nd consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 25, 2025, to shareholders of record on March 7, 2025. About Perrigo  Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Produ

    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRGO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more